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Glycoproteins present special problems for
structural genomic analysis because they often
require glycosylation in order to fold correctly,
whereas their chemical and conformational
heterogeneity generally inhibits crystallization.
We show that the ‘‘glycosylation problem’’ can
be solved by expressing glycoproteins tran-
siently in mammalian cells in the presence of
the N-glycosylation processing inhibitors, kifu-
nensine or swainsonine. This allows the correct
folding of the glycoproteins, but leaves them
sensitive to enzymes, such as endoglycosidase
H, that reduce the N-glycans to single residues,
enhancing crystallization. Since the scalability
of transient mammalian expression is now
comparable to that of bacterial systems, this
approach should relieve one of themajor bottle-
necks in structural genomic analysis.
INTRODUCTION
As early as 2003, structural genomics (SG) consortia were
contributing almost a quarter of all new structures submit-
ted to the Protein Data Bank (PDB; Terwilliger 2004). In
addition to the rapid analysis of proteins that can be ex-
pressed and crystallized readily, the opportunity afforded
by robotics and miniaturization to tackle difficult cases,
using a variety of approaches in parallel, is likely to be
amajor benefit of the SG approach. A high level of attrition
at each stage of all SG pipelines, however, is constraining
their productivity to such an extent that, according to a
recent analysis of the NIH Protein Structure Initiative
(W. Minor; personal communication), only 2.5% of cloned
genes are currently yielding structures. The two major
bottlenecks are the production of soluble protein and of
diffraction-quality crystals (Delucas et al., 2005). Glyco-Structure 15, 26proteins present special problems because they often re-
quire glycosylation in order to fold correctly, precluding
expression in bacteria (the most widely used expression
host in current SG pipelines). Moreover, following expres-
sion in mammalian and insect cells, the chemical and con-
formational heterogeneity of their carbohydrate moieties
generally inhibits crystallization. These factors probably
explain why attention to, and success with, glycoprotein
targets mean that only 10% of PDB entries, and 1% of
the structures emerging from the NIH Protein Structure
Initiative, are annotated as glycoproteins.
The dominant glycan modifications of proteins are initi-
ated by the addition of GalNAc monosaccharides to the
hydroxyl groups of serine or threonine residues, known
as O-glycosylation, or by the transfer en bloc of a doli-
chol-linked oligosaccharide precursor to asparagines
comprising Asn-X-Ser/Thr motifs, a process referred to
as N-glycosylation (Gagneux and Varki, 1999). In each
case, the glycans are extended and diversified by the
successive activities of glycosidases and/or glycosyl-
transferases. In the context of protein crystallization, O-
glycosylation constitutes less of a problem than N-glyco-
sylation, since, in the great majority of cases, O-glycans
are confined to extended, unfolded, serine-, threonine-,
and proline-rich regions of polypeptide. These so-called
STP domains are readily identified using O-glycosylation
site-predicting algorithms, such as NetOGlyc (Julenius
et al., 2005), or disorder-predicting algorithms, such as
RONN (Yang et al., 2005), and can either be deleted
from expression constructs or proteolytically cleaved at
engineered sites following purification of the protein. Alter-
natively, these regions can often be deglycosylated using
a combination of O-glycanase and neuraminidase (Leahy
et al., 1992).
Our solution to the problem of N-glycosylation in a con-
ventional crystallographic setting has relied on the use of
stable mammalian expression systems, wherein folding
and initial glycosylation proceed normally, but processing
of theN-glycans is restricted in away that allows their sub-
sequent enzymatic removal with endoglycosidase (endo)7–273, March 2007 ª2007 Elsevier Ltd All rights reserved 267
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Structural Genomic Analysis of GlycoproteinsH (Davis et al., 1993, 1995; Butters et al., 1999). Endo H
cleaves between the GlcNAc residues in the di-N-acetyl-
chitobiose core of oligomannose and hybrid-type N-gly-
cans, leaving single GlcNAc residues at each glycosyla-
tion site. The Asn-linked GlcNAc is known to dominate
glycan-protein interactions and to shield hydrophobic re-
gions of the protein surface (Petrescu et al., 2004). We
have found, with few exceptions, that the polydispersity
in solution of endo H-treated proteins is indistinguishable
from that of wild-type protein, whereas glycoproteins
completely deglycosylated with, for example, PNGase F,
tend to aggregate (Davis et al., 1995; J.A.F. and S.J.D., un-
published data).
We first produced endo H-sensitive proteins in cell lines
generated from lectin-resistant Chinese hamster ovary
(CHO) cells, such as Lec3.2.8.1 cells, that are largely inca-
pable of processing N-glycans beyond Man5GlcNAc2 in-
termediates (Davis et al., 1993). The analogous strategy
of expressing glycoproteins in insect cells, which add pau-
cimannose oligosaccharides sensitive to endoH and endo
D, has since also been successful (Kwong et al., 1999). In
an alternative strategy, we used the a-glucosidase inhibi-
tor, N-butyldeoxynojirimycin (NB-DNJ), to block the very
earliest stages of processing in cell lines generated from
wild-type CHO cells, which also yielded glycoproteins
with endo H-sensitive oligomannose N-glycans (Davis
et al., 1995). The best results were obtained when the
two approaches were combined (i.e., proteins were ex-
pressed in Lec3.2.8.1 cells in the presence of NB-DNJ)
(Butters et al., 1999). CHO cells are uniquely well suited
to the use of NB-DNJ because they are largely deficient
in a ‘‘shunt pathway,’’ wherein an endomannosidase
circumvents a-glucosidase blockade, allowing down-
stream glycan processing (Moore and Spiro 1990, 1992;
Hiraizumi et al., 1993). NB-DNJ is therefore unsuited to
use in most, if not all, other mammalian expression sys-
tems. In the case of human embryonic kidney (HEK)
293T cells, for example, less than 5% of soluble (s) B7-1
expressed transiently in the presence of NB-DNJ proved
to be endo H sensitive (K.S.B. and S.J.D., unpublished
data).
Following the initial example of rat sCD2 (PDB acces-
sion no. 1hng), these approaches, in our hands and others,
yielded structures of sCD58/CD2 (1ccz) and sCD48/CD2
chimeras (2dru), sB7-1 (1dr9), a soluble T-cell receptor
(TCR) in complex with an anti-TCR Fab (1nfd), angioten-
sin-1-converting enzyme (1o8a), and murine sCD8aa
(1bqh) and sCD8ab (2atp). Non-endo H digested,
Lec3.2.8.1-derived sICAM-1 (1ic1) and sICAM-2 (1zxq),
sCEACAM1a (1l6z), soluble semaphorin 4D (1olz), and
a sTCR/sMHC class-II complex (1d9k) also produced
crystals, presumably due to the relative uniformity of N-
glycosylation in Lec3.2.8.1 cells.
Stable, mammalian cell-based protein expression can-
not readily be implemented in a high-throughput setting
because individual clones exhibit considerable variation
in expression, necessitating clone selection. Because
the yields, efficiency, and scalability of mammalian tran-
sient expression are each approaching those of high-268 Structure 15, 267–273, March 2007 ª2007 Elsevier Ltd Althroughput bacterial systems due to the advent of new
episomal expression vectors, transfection protocols, and
tissue culture methods (Durocher et al., 2002, Geisse
and Henke 2005, Davies et al., 2005, Aricescu et al.,
2006a, 2006c; Berntzen et al., 2005), we sought analo-
gous methods for the production of endo H-sensitive gly-
coproteins in transiently transfected cells. In particular, we
wanted to be able to produce endo H-sensitive proteins in
HEK293 cells, which currently provide the benchmark for
high-level, transient mammalian protein expression (Dur-
ocher et al., 2002; Berntzen et al., 2005).
We show here that glycoproteins transiently expressed
in HEK293T cells in the presence of the N-glycosylation
processing inhibitors, kifunensine or swainsonine, are
highly sensitive to endo H. We also show that these inhib-
itors do not generally compromise overall expression
yields. Since they target highly conserved processing en-
zymes that catalyze transformations essential for complex
N-glycan formation downstream of the endomannosi-
dase-dependent shunt pathway, it can be expected that
these inhibitors will be effective in most mammalian cell-
based expression systems.
RESULTS AND DISCUSSION
We expressed soluble forms of 19A, which is a stem cell
marker protein (two IgSF domains, five glycosylation sites
[Murphy et al., 2002]), as an initial test case, and the leuko-
cyte cell surface antigen, CD48 (two IgSF domains, four
glycosylation sites [Yokoyama et al., 1991]), and the re-
ceptor tyrosine phosphatase, RPTPm (one MAM-, one
IgSF-, and four FN3-domains, 12 glycosylation sites [Geb-
bink et al., 1993]), for replication purposes. Each protein
was expressed transiently with either pEE14 (Bebbington
and Hentschell 1987) or the commercial vector pEF-
DEST51, which each contain the SV40 ori and the human
cytomegalovirus and human elongation factor 1a pro-
moter, respectively, or pHL, which contains the chicken
b-actin promoter (Aricescu et al., 2006c). Endo H sensitiv-
ity was compared at two pH values, since the stabilities of
some glycoproteins are pH sensitive (data not shown). An
overview of mammalian N-glycan processing and the ef-
fects of our strategies revealed by MALDI-TOF MS are
shown in Figure 1.
We first investigated the use of a ricin-selected, N-ace-
tylglucosaminyltransferase I (GnTI)-deficient HEK293S-
derived cell line used previously for the stable expression
of rhodopsin with Man5GlcNAc2 adducts (Reeves et al.,
2002). GnTI catalyzes the formation of hybrid-type glycans
via transfer of b1-2-linked GlcNAc to the 3-antenna of
the oligomannose substrate, Man5GlcNAc2 (Figure 1A).
This is required for formation of complex-type glycans,
as it allows cleavage of the 6-antennae mannoses by
Golgi a-mannosidase II. Transiently transfected, GnTI-
deficient HEK293S cells secreted s19A bearing only
Man5GlcNAc2-type N-glycans (Figure 1C). This protein
proved to be very sensitive to endo H at pH 5.2 and 6.5
(Figure 2A), as did sRPTPm (Crispin et al., 2006) and
sCD48 (see Figures S1 and S2, gel A, in the Supplementall rights reserved
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lian N-Linked Glycosylation Pathway in
HEK293 Cells
(A) A section of the glycosylation pathway is
illustrated.
(B–D) MALDI-TOF analysis of the glycans of
the target glycoprotein (s19A) expressed in
(B) HEK293T cells in the presence of the
a-mannosidase I (MI) inhibitor, kifunensine, at
5 mM, resulting in the addition of oligo-
mannose-type N-glycans, Man5–9GlcNAc2;
(C) ricin-resistant HEK293S cells devoid of
GnTI activity, resulting in predominantly
Man5GIcNAc2 N-glycans; and (D) HEK293T
cells in the presence of the a-mannosidase II
(MII) inhibitor, swainsonine, at 20 mM, resulting
in the addition of hybrid-type glycans. For
MALDI-TOF MS, glycans were released
directly from SDS-PAGE gel bands by over-
night PNGase F digestion. Monosaccharide
constituents are represented as follows: open
diamonds, Gal; closed diamonds, GaINAc;
open squares, Glc; closed squares, GlcNAc;
open circles, Man; stars, sialic acid; dotted
diamonds, Fuc.Data available with this article online). The extreme endo H
sensitivity of GnTI-deficient, HEK293S-derived material
contrasts with that of glycoproteins from GnTI-deficient
CHO cells (i.e., Lec1 cells: <50% sensitivity; data not
shown), or from CHO cells lacking three additional pro-
cessing enzymes (i.e., Lec3.2.8.1 cells: 50%–70% sensi-
tivity [Butters et al., 1999]). This suggests that HEK293S
cells lack an a-mannosidase activity that is present in
CHO cells (Crispin et al., 2006). Furthermore, in contrast
to proteins expressed in CHO Lec3.2.8.1 cells, GnTI-defi-
cient 293S-derived glycoproteins seem to contain only
traces of core fucose (Crispin et al., 2006), further enhanc-
ing endo H cleavage. Crystals diffracting beyond 3 A˚ grew
from endo H-treated sRPTPm expressed in GnTI-deficient
HEK293S cells (Figure 2D, left panel), whereas crystals of
the fully glycosylated protein only diffracted to a Bragg
spacing of >8 A˚.
These observations suggest that GnTI-deficient
HEK293S cells could, in principle, be used as a platform
for the high-throughput production of deglycosylatable
glycoproteins. We found, however, that expression in
these cells is only 10%–50% as high as that obtainable
in HEK293T cells, regardless of which expression vector
is used or whether the SV40 large T antigen, which is sta-
bly expressed by 293T cells and favors expression from
SV40 ori-containing plasmids, is present (data not shown).
We therefore investigated the possibility that N-glycan
processing inhibitors other than NB-DNJ might be effec-
tive in 293T cells, taking advantage of the enhanced ex-
pression capability of these cells.
The alkaloids, kifunensine and swainsonine, which are
potent inhibitors of a-mannosidases I and II, respectivelyStructure 15, 26(Figure 1A), were chosen for analysis because they act
downstream of the endomannosidase-mediated shunt
pathway likely to be responsible for the poor yields of
endo H-sensitive protein from HEK293T cells treated
with NB-DNJ (K.S.B. and S.J.D., unpublished data).
Somewhat unexpectedly, 293T cells cultured with kifu-
nensine and swainsonine produced larger quantities of
s19A than 293T cells alone (by 30% and 10%, respec-
tively; data not shown). In the case of kifunensine, it is
likely that this is due to its inhibition of ER-associated deg-
radation (Tokunaga et al., 2003). N-glycans released from
s19A expressed in the presence of kifunensine and swain-
sonine were of the oligomannose- and hybrid-types, re-
spectively (Figures 1B and 1D). The complexity of the
swainsonine-induced hybrid-type structures (Figure 1D)
reveals the presence of the GnTI-dependent activities of
several glycosyltransferases, including GnTIII, which
adds bisecting b1-4GlcNAc, and FUT8, which catalyzes
the transfer of a1-6-linked fucose to the reducing terminal
GlcNAc. Endo H treatment of s19A (Figures 2B and 2C),
sRPTPm (Figure S1), and sCD48 (Figure S2) secreted in
the presence of both inhibitors yielded essentially gly-
can-free material at pH 5.2. The digestion of sRPTPm
and sCD48 at pH 6.5 was less effective for swainsonine-
than for kifunensine-derived material (Figures S1 and S2,
gels B and C), reflecting the lower endo H susceptibility
of core a1-6 fucosylated hybrid-type glycans and the
stringent inhibition of core fucosylation by kifunensine
(Crispin et al., 2006). s19A, secreted in the presence of
swainsonine, crystallized (Figure 2D, right panel), and
these crystals diffracted to <3 A˚; we have yet to obtain
crystals of s19A from kifunensine-treated cultures. Total7–273, March 2007 ª2007 Elsevier Ltd All rights reserved 269
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pH 6.5 than at pH 5.2 (Figure S2), signaling the pH sensi-
tivity of this protein (crystallization of sCD48 has not been
attempted).
Our results show that kifunensine and swainsonine can
be used to prepare deglycosylatable glycoproteins in
293T cells, without compromising protein yield. There is
every reason to expect that these inhibitors will be effec-
tive in most mammalian expression systems, given (1)
their activity downstream of the endomannosidase shunt
pathway, and (2) the highly conserved structures of the
active sites and inhibitor-binding properties of a-mannosi-
dase I and II from organisms as diverse as mammals, in-
sects, and yeast (Kawar et al., 2000; van den Elsen
et al., 2001; Tempel et al., 2004). We can already confirm
Figure 2. Endo HDigestion of s19A Produced in HEK293 Cells
under Various Conditions
(A–C) SDS-PAGE gels, run under reducing conditions, of endo H- or
PNGase F-treated s19A expressed in (A) GnTI-deficient HEK293S
cells, (B) HEK293T cells cultured with 5 mM kifunensine, and (C)
HEK293T cells cultured with 20 mM swainsonine. In each case, 5 mg
of purified s19A was treated at 37C with 1 kU or 0.25 kU of endo H
at the indicated pH, or at 37C with 0.5 kU of PNGase F at pH 7.4,
for 6 hr. For the endo H digests, identity of the products indicates
that the digestions have gone to completion.
(D) Crystals of endo H-treated sRPTPm expressed in GnTI-deficient
HEK293S cells (left panel) and endo H-treated s19A expressed in
HEK293T cells in the presence of swainsonine (right panel). See Sup-
plemental Data for the endo H-sensitivity and SDS-PAGE analysis of
sRPTPm. Data have been collected in space groups C2 and P212121
for RPTPm and s19A, respectively (see Experimental Procedures).270 Structure 15, 267–273, March 2007 ª2007 Elsevier Ltd All rthat kifunensine is effective in transiently transfected 293E
cells (Durocher et al., 2002) and stably transfected CHO-
K1 cells (Davis et al., 1990; data not shown). Kifunensine
has the practical advantage over swainsonine of being ac-
tive at 2- to 4-fold-lower concentrations, making it much
more cost effective. Moreover, treatment with kifunensine
leads to a much more homogeneous product, since it is
better at suppressing the formation of core-fucosylated
hybrid structures, which are somewhat endo H resistant.
For most proteins, this is likely to be a significant advan-
tage. However, in the case of s19A, we obtained crystals
of endoH-treated protein from swainsonine-treated but
not kifunensine-treated cultures, suggesting that the fu-
cose residues remaining after removal of the bulk of
each glycan can contribute to the crystallizability of the
protein. Therefore, both inhibitors could be trialed for the
crystallization of recalcitrant proteins.
It is worth noting that other approaches for expressing
deglycosylatable glycoproteins, or glycoproteins with
minimal or no glycosylation, also exist. The yeast, Pichia
pastoris, can be used to express glycoproteins with
endo H-sensitive N-glycans, although, in our experience,
certain classes of mammalian proteins fail to fold effi-
ciently in these cells (S.J.D., unpublished data; Aricescu
et al., 2006a). Expression in insect cells (e.g., S. frugiperda
[Sf9]) has the advantage that compact N-glycans domi-
nated by the fucosylated Man3GlcNAc2Fuc pauciman-
nose hexasaccharide are added (Figure S3A). This struc-
ture lacks the extreme structural and conformational
heterogeneity characteristic of mammalian complex-
typeN-glycans, accounting for themany structures of fully
glycosylated, insect cell-expressed proteins that have
been published (e.g., Choe et al., 2005). Endo D and
endo H have also been used in combination to reduce
the Man3GlcNAc2Fuc hexasaccharide and residual oligo-
mannose-type glycans, respectively, to single, potentially
fucosylated, GlcNAc residues on HIV-1 gp120 (Kwong
et al., 1999), an observation we now extend to sRPTPm
(Figure S3A). Significant problems with this approach,
however, are the time scales and expense of insect cell
culture, and, in our experience, protein yields that are at
least several-fold lower than those obtainable via transient
expression in HEK293T cells. sRPTPm, for example, is ex-
pressed at 1 mg/l and 35 mg/l in Sf9 and HEK293T cells,
respectively (data not shown). Finally, mutation of glyco-
sylation sites prior to expression has facilitated the crys-
tallization of, among other proteins, the ADP-ribosyl
cyclase CD157 (1isf), Zn-a2-glycoprotein (1t7v), butyryl-
cholinesterase (1xlw), angiotensin I-converting enzyme
(2iul, 2iux), and procathepsin (1mir). In several cases,
a subset of the glycosylation sites had to be left intact in
order for these proteins to fold correctly. A complemen-
tary strategy for identifying nonessential glycosylation
sites, by virtue of their being variably occupied in the na-
tive protein, has recently been described (Nettleship
et al., 2007).
It has been argued that SG methodologies could be
broadened to better accommodate targets of higher tech-
nical difficulty and greater scientific ‘‘impact’’ (Aricescuights reserved
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we present ought to facilitate the analysis of glycopro-
teins, not only in general structural biology laboratories,
but also by bringing this important class ofmolecule within
reach of existing SG pipelines.
EXPERIMENTAL PROCEDURES
Preparation of Constructs
A cDNA fragment encoding the sRPTPm extracellular region (residues
1–724) was amplified by polymerase chain reaction (PCR) with the
phFL vector as template (a gift fromM. Gebbink, University of Utrecht,
The Netherlands [Gebbink et al., 1993]) and subcloned into the pHL ex-
pression vector (Aricescu et al., 2006b) and pFastBac1 (Invitrogen Ltd,
Paisley, UK) in framewith a C-terminal LysHis6 tag. PCRwas also used
to amplify cDNA fragments encoding the human s19A and sCD48 ex-
tracellular regions (residues 1–222 and 1–223, respectively) and C-ter-
minal LysHis6 tags from plasmid templates (M.T. Vuong, personal
communication). The genes were inserted into the expression vectors
pEF-DEST51 (Invitrogen Ltd, Paisley, UK) by Gateway cloning, pHL
(Aricescu et al., 2006c), or pEE14 (Bebbington and Hentschell, 1987).
Expression in HEK293T Cells
HEK293T (ATCC no. CRL-1573) and GnTI-deficient HEK293S cells (a
gift from H.G. Khorana and P.J. Reeves, Massachusetts Institute of
Technology [Reeves et al., 2002]), each cultured as adherent mono-
layers in Dulbecco’s modified Eagle’s medium (Sigma-Aldrich Com-
pany Ltd., Gillingham, UK) supplemented with 10% fetal calf serum
(v/v; Sigma-Aldrich Company Ltd.), L-glutamine and nonessential
amino acids (Invitrogen Ltd., Paisley, UK), were transiently transfected
with the ‘‘25 kDa branched’’ form of polyethyleneimine (PEI; Sigma-
Aldrich Company Ltd.) (Durocher et al., 2002; Kichler 2004; Demeneix
and Behr 2005). Briefly, the PEI was diluted to 1 mg/ml from a stock
solution of 100 mg/ml and pH-adjusted to pH 7 with HCl. The plas-
tic-adherent cells were grown to90% confluency in 3–4 Nunc Triple-
Flask tissue culture flasks (3 3 176 cm2/flask surface area; Cole-
Parmer Instrument Company Ltd., Hanwell, UK) in 120 ml of medium
per flask. Plasmid DNA (150 mg/flask) was added to 5 ml of serum-
free medium and mixed with 300 ml/flask of PEI (1 mg/ml), followed
by brief vortexing. The solution was incubated for 10 min at room tem-
perature to allow DNA-PEI complex formation. During complex forma-
tion, medium from the plates to be transfected was replaced with
120 ml/flask of fresh medium containing swainsonine (Gross et al.,
1983) or kifunensine (Toronto Research Chemicals, North York, ON,
Canada) (Elbein et al., 1990) at final concentrations of 20 mM and 5
mM, respectively, and fetal calf serum at a concentration of 2% (v/v).
Finally, the DNA-PEI complex was added to the flask, with brief rota-
tion to allow mixing. Four to five days later, the supernatant was har-
vested for protein purification.
Glycoprotein Purification
Tissue culture supernatant, typically up to 0.5 liter, containing the se-
creted protein, was harvested and debris removed by centrifugation
at 5000 3 g at 4C for 20 min. An equal volume of PBS (pH 8.0),
0.05% NaN3, was added, along with 2–4 ml/l of a 50% slurry of Ni-
NTA agarose beads (QIAGEN, West Sussex, UK). The mixture was
gently stirred at 4C overnight and the beads collected by centrifuga-
tion at 200 3 g for 5 min in 50 ml tubes (Falcon, BD Biosciences, Ox-
ford, UK) at 4C. The beads were poured into an EconoColumn (Bio-
Rad Laboratories Ltd., Hemel Hempstead, UK) and washed with 10
column volumes of PBS (pH 8.0) prior to pre-elution with 2 volumes
of 10 mM imidazole (pH 8.0) and elution with 2 volumes of 250 mM im-
idazole (pH 8.0). Eluting fractions containing protein of the expected
size, according to SDS-PAGE analysis, were pooled and concentrated
to300 ml for further purification by Sephacryl S-200 gel filtration in 10
mM HEPES (pH 7.4), 150 mM NaCl. Fractions containing the proteinsStructure 15, 267at >95% purity, according to SDS-PAGE analysis, were pooled and
stored at 4C.
Protein Deglycosylation
The purified proteins were deglycosylated with endo Hf (New England
Biolabs, Hitchin, UK). Trial digests of 5 mg of protein at 37C, with a se-
ries of 4-fold dilutions of endo Hf starting with 500 U of the enzyme in
a final volume of 20 ml of 0.1 MNaOAc at pH 5.2, were used to estimate
the amount of endo Hf required for full deglycosylation. Generally, the
trial incubations were done for 1 hr and 3 hr in order to limit the amount
of time that larger amounts of the protein would eventually have to be
kept at low pH (i.e., pH 5.2). The extent of digestion was monitored by
SDS-PAGE analysis; identity of the 1 hr and 3 hr samples was taken to
indicate that digestion had gone to completion within 1 hr. For highly
pH-sensitive protein (i.e., protein that visibly precipitates during the
course of the digestion at pH 5.2 [e.g., sRPTPm and sCD48]), longer di-
gestions at the nonoptimal pH 7.4 were used, necessitating larger
amounts of enzyme. For large-scale digestion of s19A expressed in
the presence of swainsonine, 0.6 mg of protein at 0.17 mg/ml in 0.1
M NaOAc (pH 5.2) was digested with 35.7 kU of endo Hf for 1 hr at
37C. For the digestion of sRPTPm expressed in GnTI-deficient
HEK293S cells, 2.3 mg of protein at 1.5 mg/ml in 10 mM HEPES
(pH 7.4), 150 mM NaCl, was digested with 92 kU of endo Hf for 6 hr
at 37C. Following digestion at low pH (i.e., pH 5.2), the samples
were neutralized with an equal volume of 1 M Tris (pH 8.0). Prior to fur-
ther purification, the digested samples were centrifuged at 5000 3 g
for 5 min to remove any precipitates, and then concentrated to
0.4–0.5 ml. Deglycosylated protein was finally separated from endo
Hf-resistant protein by Sephadex S-200 gel filtration in 10 mM HEPES
(pH 7.4), 150 mM NaCl. Overall yields of deglycosylated protein were
in the region of 25%–50%.
Crystallization
Crystals of sRPTPm, expressed in GnTI-deficient 293S cells and degly-
cosylated with endo Hf, were grown by sitting-drop vapor diffusion at
22C. Droplets (100 nl) of protein at 3.7 mg/ml in 10 mM HEPES (pH
7.4), 150 mM NaCl, mixed with 100 nl of reservoir solution, were set
in 96-well plates (Greiner Bio-One Ltd, Stonehouse, UK) by a Cartesian
Technologies MIC4000 robot, as previously described (Walter et al.,
2005). Crystals in space group C2 (a = 167.3 A˚, b = 69.3 A˚, c = 97.5 A˚,
b = 113.5) appeared after 18 days against a reservoir containing poly-
ethylene glycol SMEAR (22.5% w/v) (Newman et al., 2005), 100 mM
bis-Tris propane (pH 6.5), and 200 mM potassium thiocyanate. Crys-
tals were cryoprotected with perfluoropolyether oil (PFO-X125/03;
Lancaster Synthesis, Inc., Windham, NH), and data were collected at
beamline ID29 (ESRF, Grenoble, France). Diffraction data to 3 A˚ with
99.5% completeness and an Rmerge of 17.4% were collected.
Crystals of s19A, expressed in HEK293T cells with 20 mM swainso-
nine and deglycosylated with endo Hf, were grown by sitting-drop va-
por diffusion at 22C. Droplets (100 nl) of this protein at 6 mg/ml in 10
mM HEPES (pH 7.4), 150 mM NaCl, mixed with 100 nl of reservoir so-
lution, were also set in 96-well plates by the Cartesian Technologies
MIC4000 robot. Crystals in space group P212121 (a = 64.75 A˚, b =
55.12 A˚, c = 156.67 A˚; a = b = g = 90) appeared against a reservoir
containing 10 mM magnesium chloride, 30% v/v polyethylene glycol
400, 100 mM potassium chloride in 50 mM Tris-HCl (pH 8.5), with pH
adjustment according to Walter et al. (2005). Diffraction data to 2.6 A˚
with 97.1% completeness and an Rmerge of 12.0% were collected.
Release of N-Linked Glycans by Protein N-Glycanase
F for MALDI-TOF Analysis
Coomassie blue-stained bands containing approximately 10 mg of tar-
get glycoprotein were excised from reducing SDS-PAGE gels and
washed with 20 mM NaHCO3 (pH 7.0). The washed gel bands were
dried in a vacuum centrifuge before rehydration in 30 ml of 30 mM
NaHCO3 (pH 7), containing 100 U/ml of protein N-glycanase F
(PNGase F; Glyko Inc., Novato, CA, USA). After incubation for 12 hr
at 37C, the enzymatically released N-linked glycans were eluted–273, March 2007 ª2007 Elsevier Ltd All rights reserved 271
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Structural Genomic Analysis of Glycoproteinswith water. Salts were removed by incubation at room temperature (5
min) with 200 ml of an acid-activated AG-50W slurry (200–400 mesh;
Bio-Rad), which was removed by filtration with a 0.45 ml pore-size
filter (Millex-LH, hydrophobic polytetrafluoroethylene).
MALDI-TOF Mass Spectrometry of N-Linked Glycans
Positive ion MALDI-TOF mass spectra were recorded with a Waters-
Micromass (Manchester, UK) TofSpec 2E reflectron-TOF mass
spectrometer operated under the following conditions: accelerating
voltage, 20 kV; pulse voltage, 3.0 kV; time-lag focusing delay, 500
ns (setting 39); laser repetition rate, 10 Hz. Aqueous glycan samples
(0.5 ml) were mixed on the MALDI target with the matrix (0.5 ml of
a saturated solution of 2,5 dihydroxybenzoic acid in acetonitrile), al-
lowed to dry under ambient conditions, and recrystallized from eth-
anol (0.2 ml). Structural assignments of all MS spectra were made by
composition, based on the characteristic fragmentation of molecular
ions by collision-induced decomposition (Harvey 2005).
Supplemental Data
Supplemental Data, including supplemental figures, are available on-
line at http://www.structure.org/cgi/content/full/15/3/267/DC1/.
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